JP2020536069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536069A5 JP2020536069A5 JP2020518057A JP2020518057A JP2020536069A5 JP 2020536069 A5 JP2020536069 A5 JP 2020536069A5 JP 2020518057 A JP2020518057 A JP 2020518057A JP 2020518057 A JP2020518057 A JP 2020518057A JP 2020536069 A5 JP2020536069 A5 JP 2020536069A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- formula
- methyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 substituted Chemical class 0.000 claims description 134
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 230000003097 anti-respiratory effect Effects 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 12
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 11
- SWQQELWGJDXCFT-PNHWDRBUSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide Chemical compound C#CC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SWQQELWGJDXCFT-PNHWDRBUSA-N 0.000 claims description 8
- DKORMNNYNRPTBJ-UHFFFAOYSA-N 2-[[6-[[2-(3-hydroxypropyl)-5-methylanilino]methyl]-2-(3-morpholin-4-ylpropylamino)benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol Chemical compound CC1=CC=C(CCCO)C(NCC=2C=C3N(CC=4C(=CC=C(C)N=4)O)C(NCCCN4CCOCC4)=NC3=CC=2)=C1 DKORMNNYNRPTBJ-UHFFFAOYSA-N 0.000 claims description 8
- AWSRKKBIPSQHOJ-IBCQBUCCSA-N 4-amino-1-[(2r,3r,4r,5r)-5-(chloromethyl)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](F)[C@H](O)[C@](CO)(CCl)O1 AWSRKKBIPSQHOJ-IBCQBUCCSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- ZETYKEPFFRMVBX-UHFFFAOYSA-N rfi 641 Chemical compound NC(=O)CN(CC(N)=O)S(=O)(=O)C1=CC=CC(NC=2N=C(NC=3C=C(C(C=4C(=CC(NC=5N=C(NC=6C=C(C=CC=6)S(=O)(=O)N(CC(N)=O)CC(N)=O)N=C(NC=6C=C(C=CC=6)S(=O)(=O)N(CC(N)=O)CC(N)=O)N=5)=CC=4)S(O)(=O)=O)=CC=3)S(O)(=O)=O)N=C(NC=3C=C(C=CC=3)S(=O)(=O)N(CC(N)=O)CC(N)=O)N=2)=C1 ZETYKEPFFRMVBX-UHFFFAOYSA-N 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 4
- ASILHPOFVOONEE-UHFFFAOYSA-N 1,4-bis(3-methylpyridin-4-yl)-1,4-diazepane Chemical compound CC1=CN=CC=C1N1CCN(C=2C(=CN=CC=2)C)CCC1 ASILHPOFVOONEE-UHFFFAOYSA-N 0.000 claims description 4
- MTPVBMVUENFFLL-HXUWFJFHSA-N 1-(2-fluorophenyl)-3-[(3s)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]urea Chemical compound FC1=CC=CC=C1NC(=O)N[C@@H]1C(=O)NC2=CC=CC=C2C(C=2C=CC=CC=2)=N1 MTPVBMVUENFFLL-HXUWFJFHSA-N 0.000 claims description 4
- KSHJXDWYTZJUEI-UHFFFAOYSA-N 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one Chemical compound N=1C2=CC=CC=C2N(CCCCO)C=1CN(C1=O)C2=CN=CC=C2N1C1CC1 KSHJXDWYTZJUEI-UHFFFAOYSA-N 0.000 claims description 4
- GVVIAZOBDFNZPB-UHFFFAOYSA-N 1h-1-benzazepine-2-carboxamide Chemical compound N1C(C(=O)N)=CC=CC2=CC=CC=C21 GVVIAZOBDFNZPB-UHFFFAOYSA-N 0.000 claims description 4
- BLUJRJMLDHEMRX-UHFFFAOYSA-N 2-[[2-hydroxy-5-[(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(5-methyltetrazol-1-yl)iminomethyl]phenol Chemical compound Cc1nnnn1N=Cc1ccc(O)c(c1)C(c1ccc(O)cc1)c1cc(C=Nn2nnnc2C)ccc1O BLUJRJMLDHEMRX-UHFFFAOYSA-N 0.000 claims description 4
- BLUJRJMLDHEMRX-BMNRKXRESA-N 2-[[2-hydroxy-5-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenol Chemical compound Cc1nnnn1\N=C\c2ccc(O)c(c2)C(c3ccc(O)cc3)c4cc(\C=N\n5nnnc5C)ccc4O BLUJRJMLDHEMRX-BMNRKXRESA-N 0.000 claims description 4
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 4
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- LNZKOJMCKWERFO-UHFFFAOYSA-N 2H-thieno[2,3-d]azepine-2-carboxamide Chemical compound S1C(C=C2C1=CC=NC=C2)C(=O)N LNZKOJMCKWERFO-UHFFFAOYSA-N 0.000 claims description 4
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 claims description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 108010014726 Interferon Type I Proteins 0.000 claims description 4
- 102000002227 Interferon Type I Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- MFTWVTURYAGJPH-UHFFFAOYSA-N N-(2-oxa-7-azaspiro[3.5]nonan-7-yl)pyridine-3-carboxamide Chemical compound C(C1=CN=CC=C1)(=O)NN1CCC2(COC2)CC1 MFTWVTURYAGJPH-UHFFFAOYSA-N 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- MJVKYGMNSQJLIN-KYZVSKTDSA-N [(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(chloromethyl)-4-fluoro-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate Chemical compound F[C@@H]1[C@H](OC(=O)C(C)C)[C@](COC(=O)C(C)C)(CCl)O[C@H]1N1C(=O)N=C(N)C=C1 MJVKYGMNSQJLIN-KYZVSKTDSA-N 0.000 claims description 4
- WUMYBFXWUJTWTB-UHFFFAOYSA-N [hydroxy(methoxy)phosphoryl] phosphono hydrogen phosphate Chemical compound COP(O)(=O)OP(O)(=O)OP(O)(O)=O WUMYBFXWUJTWTB-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- YUCHAYRHHXJNQK-UHFFFAOYSA-N amitivir Chemical compound N#CNC1=NN=CS1 YUCHAYRHHXJNQK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- CAKNZLNLUKXNCC-UHFFFAOYSA-N carbamoyl benzoate Chemical compound NC(=O)OC(=O)C1=CC=CC=C1 CAKNZLNLUKXNCC-UHFFFAOYSA-N 0.000 claims description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 108700002314 gontivimab Proteins 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- CTIRNXGIOKPVOM-UHFFFAOYSA-N imidazo[4,5-c]pyridin-2-one Chemical compound C1=CN=CC2=NC(=O)N=C21 CTIRNXGIOKPVOM-UHFFFAOYSA-N 0.000 claims description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 108010018844 interferon type III Proteins 0.000 claims description 4
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229940014456 mycophenolate Drugs 0.000 claims description 4
- 229960000951 mycophenolic acid Drugs 0.000 claims description 4
- UHHHWFCTIQAQKF-UHFFFAOYSA-N n-cyclopropyl-6-[4-[[2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)pyridine-3-carbonyl]amino]benzoyl]-4,5-dihydrothieno[3,2-d][1]benzazepine-2-carboxamide Chemical compound C=1C=2CCN(C(=O)C=3C=CC(NC(=O)C=4C(=NC=CC=4)N4CCC5(COC5)CC4)=CC=3)C3=CC=CC=C3C=2SC=1C(=O)NC1CC1 UHHHWFCTIQAQKF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 4
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 claims description 4
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- PMAKDNHZVBVWFM-UHFFFAOYSA-N sodium;cyano(1,3,4-thiadiazol-2-yl)azanide Chemical compound [Na+].N#C[N-]C1=NN=CS1 PMAKDNHZVBVWFM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 4
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims description 4
- 229950006081 taribavirin Drugs 0.000 claims description 4
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 101710141454 Nucleoprotein Proteins 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 229940121649 protein inhibitor Drugs 0.000 claims description 3
- 239000012268 protein inhibitor Substances 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 1
- 229940125874 fusion protein inhibitor Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 description 16
- 0 CC=C(C(C(*)=NC1(*)N(*)c2nc3ccccc3[o]2)=CNC)N(*)C1=O Chemical compound CC=C(C(C(*)=NC1(*)N(*)c2nc3ccccc3[o]2)=CNC)N(*)C1=O 0.000 description 6
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566160P | 2017-09-29 | 2017-09-29 | |
| US201762566159P | 2017-09-29 | 2017-09-29 | |
| US62/566,159 | 2017-09-29 | ||
| US62/566,160 | 2017-09-29 | ||
| PCT/US2018/053361 WO2019067864A1 (en) | 2017-09-29 | 2018-09-28 | PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536069A JP2020536069A (ja) | 2020-12-10 |
| JP2020536069A5 true JP2020536069A5 (https=) | 2021-11-04 |
| JP7198811B2 JP7198811B2 (ja) | 2023-01-04 |
Family
ID=65903295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518057A Active JP7198811B2 (ja) | 2017-09-29 | 2018-09-28 | Ｒｓｖ阻害剤としての組み合わせ医薬剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10881666B2 (https=) |
| EP (1) | EP3687543B1 (https=) |
| JP (1) | JP7198811B2 (https=) |
| KR (1) | KR102645995B1 (https=) |
| CN (1) | CN111386118B (https=) |
| AU (1) | AU2018339068B2 (https=) |
| BR (1) | BR112020006334A2 (https=) |
| CA (1) | CA3077309A1 (https=) |
| MX (1) | MX2020004084A (https=) |
| TW (1) | TWI794297B (https=) |
| WO (1) | WO2019067864A1 (https=) |
| ZA (1) | ZA202002139B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY197231A (en) | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| AU2018221820B2 (en) | 2017-02-16 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| US10752598B2 (en) | 2017-06-07 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as RSV inhibitors |
| WO2019006291A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| CA3077309A1 (en) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as rsv inhibitors |
| US10647711B2 (en) | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| US10975094B2 (en) | 2018-04-11 | 2021-04-13 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| KR102926658B1 (ko) | 2019-03-18 | 2026-02-11 | 이난타 파마슈티칼스, 인코포레이티드 | Rsv 억제제로서의 벤조디아제핀 유도체 |
| WO2020210246A1 (en) | 2019-04-09 | 2020-10-15 | Enanta Pharmaceuticals, Inc, | Heterocyclic compounds as rsv inhibitors |
| US10689374B1 (en) * | 2019-07-12 | 2020-06-23 | United Arab Emirates University | Pyrimidine-thiazolidinone derivatives |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| AU2020357452B2 (en) * | 2019-10-04 | 2026-01-29 | Enanta Pharmaceuticals, Inc | Antiviral heterocyclic compounds |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| CN111978312B (zh) * | 2020-09-18 | 2023-05-05 | 黄淮学院 | 5-芳基-1,3,4-噻二唑/1,3,4-噁二唑-2-胺类化合物及制备方法和应用 |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| IL305189A (en) | 2021-02-26 | 2023-10-01 | Enanta Pharm Inc | Heterocyclic antiviral compounds |
| CN114014856B (zh) * | 2021-11-26 | 2023-12-22 | 嘉兴安谛康生物科技有限公司 | 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶类衍生物 |
| CN114426496A (zh) * | 2022-01-13 | 2022-05-03 | 山东莱福科技发展有限公司 | 一种二苯甲酮类医药中间体的制备方法 |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| US12162857B2 (en) | 2022-04-27 | 2024-12-10 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| WO2024174953A1 (zh) * | 2023-02-21 | 2024-08-29 | 苏州隆博泰药业有限公司 | 苯并咪唑类衍生物及其医药用途 |
| WO2025101560A1 (en) * | 2023-11-07 | 2025-05-15 | Enanta Pharmaceuticals, Inc. | Crystal forms of an anti-rsv agent |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH573928A5 (https=) | 1973-07-30 | 1976-03-31 | Crc Ricerca Chim | |
| IT1087017B (it) | 1977-10-18 | 1985-05-31 | Ravizza Spa | Processo per la preparazione di un 7-cloro-5-(2-clorofenil)-benzodiaze pinone |
| CA1332410C (en) | 1984-06-26 | 1994-10-11 | Roger M. Freidinger | Benzodiazepine analogs |
| FR2641280B1 (fr) | 1988-12-29 | 1994-01-21 | Roussel Uclaf | Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments |
| US5571809A (en) | 1989-04-20 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | The treatment of HIV-1 infection using certain pyridodiazepines |
| AU2759692A (en) | 1991-10-24 | 1993-05-21 | Glaxo Group Limited | Benzodiazepine derivatives as antagonists of gastrin and/or cholecystokinin |
| GB9201180D0 (en) | 1992-01-21 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
| JPH07505155A (ja) | 1992-03-24 | 1995-06-08 | メルク シヤープ エンド ドーム リミテツド | コレシストキニン及び／又はガストリン拮抗活性を有する３−ウレイド置換ベンゾジアゼピン−２−オン及び治療におけるその使用 |
| GB9307833D0 (en) | 1993-04-15 | 1993-06-02 | Glaxo Inc | Modulators of cholecystokinin and gastrin |
| KR960702444A (ko) | 1993-05-13 | 1996-04-27 | 고야 마사시 | 3-아미노아제핀 화합물 및 그 의약 용도(3-aminoazepine compound and pharmaceutical use thereof) |
| EP2359831A3 (en) | 1999-04-30 | 2012-02-01 | The Regents of the University of Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
| BR0314595A (pt) | 2002-09-20 | 2005-08-09 | Arrow Therapeutics Ltd | Uso de um derivado de benzodiazepina ou um sal farmaceuticamente aceitável deste, inalador ou nebulisador, produto, usos de um produto e de um composto ou sal farmaceuticamente aceitável deste, derivado de benzodiazepina, composto, e, composição farmacêutica |
| GB0312365D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
| WO2005042530A1 (en) | 2003-10-30 | 2005-05-12 | Boehringer Ingelheim (Canada) Ltd. | Rsv polymerase inhibitors |
| EP1697343B1 (en) | 2003-12-18 | 2009-07-01 | Tibotec Pharmaceuticals Ltd. | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication |
| GB0406280D0 (en) | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Chemical compounds |
| GB0406282D0 (en) * | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Therapeutic compounds |
| GB0406279D0 (en) | 2004-03-19 | 2004-04-21 | Arrow Therapeutics Ltd | Therapeutic compounds |
| US20070293482A1 (en) | 2004-03-19 | 2007-12-20 | Novartis Pharmaceuticals Corporation | Process for Preparing Benzodiazepines |
| US20060083741A1 (en) | 2004-10-08 | 2006-04-20 | Hoffman Rebecca S | Treatment of respiratory syncytial virus (RSV) infection |
| TWI444187B (zh) | 2005-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之噻吩化合物 |
| CA2612263C (en) | 2005-06-20 | 2015-04-14 | Tibotec Pharmaceuticals Ltd. | 1-(2-amino-3-(substituted alkyl)-3h-benzimidazolylmethyl)-3-subtituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus |
| EP2086966B1 (en) | 2006-11-17 | 2011-09-14 | GlaxoSmithKline LLC | 2-carboxy thiophene derivatives as anti viral agents |
| WO2010103306A1 (en) | 2009-03-10 | 2010-09-16 | Astrazeneca Uk Limited | Benzimidazole derivatives and their use as antivaral agents |
| WO2011005842A1 (en) | 2009-07-09 | 2011-01-13 | Gilead Sciences, Inc. | Anti-rsv compounds |
| RS54645B1 (sr) | 2009-11-05 | 2016-08-31 | Glaxosmithkline Llc | Benzodiazepin kao inhibitor bromodomena |
| WO2011151651A1 (en) | 2010-06-03 | 2011-12-08 | Arrow Therapeutics Limited | Benzodiazepine compounds useful for the treatment of hepatitis c |
| MA34392B1 (fr) | 2010-06-24 | 2013-07-03 | Gilead Sciences Inc | Pyrimidines en tant qu'agents antiviraux |
| BR122020020745B8 (pt) | 2010-07-22 | 2023-10-31 | Gilead Sciences Inc | Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende |
| US8796303B2 (en) | 2010-11-26 | 2014-08-05 | Biota Scientific Management Pty Ltd. | Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections |
| TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| TWI530495B (zh) | 2010-12-16 | 2016-04-21 | 健生科學愛爾蘭無限公司 | 苯并咪唑呼吸道融合病毒抑制劑 |
| TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
| TWI541241B (zh) | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| EP2766370B1 (en) | 2011-10-11 | 2016-08-03 | F.Hoffmann-La Roche Ag | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |
| CA2858096C (en) | 2011-12-22 | 2020-06-23 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
| CN106986869A (zh) | 2012-04-17 | 2017-07-28 | 吉利德科学公司 | 用于抗病毒治疗的化合物和方法 |
| EP2863204B1 (en) | 2012-06-14 | 2017-11-01 | Sony Corporation | Information processing device, information processing method, and information processing program |
| KR20150032283A (ko) | 2012-06-15 | 2015-03-25 | 얀센 알 앤드 디 아일랜드 | 호흡기 합포체 바이러스의 항바이러스제로서의 헤테로사이클로 치환된 1,3-디하이드로-2h-벤즈이미다졸-2-온 유도체 |
| WO2013186334A1 (en) | 2012-06-15 | 2013-12-19 | Janssen R&D Ireland | 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents |
| LT2864323T (lt) | 2012-06-15 | 2017-07-25 | Janssen Sciences Ireland Uc | 1,3-dihidro-2h-benzimidazol-2-ono dariniai, turintys heterociklų pakaitų, kaip antivirusiniai agentai prieš respiratorinį sincitinį virusą |
| EA201590023A1 (ru) | 2012-06-15 | 2015-05-29 | ЯНССЕН Ар ЭНД Ди АЙРЛЭНД | Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса |
| RU2015102792A (ru) | 2012-07-10 | 2016-08-27 | Ф. Хоффманн-Ля Рош Аг | Новые индазолы для лечения и профилактики респираторно-синцитиальной вирусной инфекции |
| AU2013305759C1 (en) | 2012-08-23 | 2018-01-18 | Janssen Biopharma, Inc. | Compounds for the treatment of paramoxyvirus viral infections |
| WO2014047369A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
| WO2014047397A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors |
| EP2897954B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
| BR112015008325B1 (pt) | 2012-10-16 | 2022-01-25 | Janssen Sciences Ireland Uc | Compostos antivirais contra o rsv, seu uso e composição farmacêutica que os compreende |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| TWI651300B (zh) | 2013-05-17 | 2019-02-21 | 健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| WO2014209983A1 (en) | 2013-06-26 | 2014-12-31 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| NZ716822A (en) | 2013-08-21 | 2017-10-27 | Alios Biopharma Inc | Antiviral compounds |
| AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
| TWI678369B (zh) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| SG11201700851WA (en) | 2014-08-05 | 2017-03-30 | Alios Biopharma Inc | Combination therapy for treating a paramyxovirus |
| BR112017005104B1 (pt) | 2014-10-10 | 2022-08-23 | Pulmocide Limited | Derivados de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina, seus usos, composição farmacêutica e processo para a preparação dos mesmos |
| JP6694886B2 (ja) | 2014-12-18 | 2020-05-20 | プルモシデ リミテド | ４，５−ジヒドロ−６Ｈ−チエノ［３，２−ｄ］ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス（ＲＳＶ）感染を治療するためのその使用 |
| MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
| GB201506448D0 (en) | 2015-04-16 | 2015-06-03 | Univ Durham | An antimicrobial compound |
| MY197231A (en) * | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| CN108699077B (zh) | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
| MA44007A (fr) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| US10626126B2 (en) | 2016-04-08 | 2020-04-21 | Pulmocide Limited | Compounds |
| US10398706B2 (en) | 2017-01-06 | 2019-09-03 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as RSV inhibitors |
| AU2018221820B2 (en) | 2017-02-16 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| US10752598B2 (en) | 2017-06-07 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as RSV inhibitors |
| WO2019006291A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| CA3077309A1 (en) | 2017-09-29 | 2019-04-04 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as rsv inhibitors |
| US10647711B2 (en) | 2017-11-13 | 2020-05-12 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as RSV inhibitors |
| NZ764647A (en) | 2017-11-13 | 2025-12-19 | Enanta Pharm Inc | Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives |
| US10975094B2 (en) | 2018-04-11 | 2021-04-13 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| KR102926658B1 (ko) | 2019-03-18 | 2026-02-11 | 이난타 파마슈티칼스, 인코포레이티드 | Rsv 억제제로서의 벤조디아제핀 유도체 |
| AU2020357452B2 (en) | 2019-10-04 | 2026-01-29 | Enanta Pharmaceuticals, Inc | Antiviral heterocyclic compounds |
-
2018
- 2018-09-28 CA CA3077309A patent/CA3077309A1/en active Pending
- 2018-09-28 KR KR1020207011858A patent/KR102645995B1/ko active Active
- 2018-09-28 BR BR112020006334-7A patent/BR112020006334A2/pt not_active IP Right Cessation
- 2018-09-28 JP JP2020518057A patent/JP7198811B2/ja active Active
- 2018-09-28 CN CN201880076451.XA patent/CN111386118B/zh not_active Expired - Fee Related
- 2018-09-28 EP EP18862419.1A patent/EP3687543B1/en active Active
- 2018-09-28 AU AU2018339068A patent/AU2018339068B2/en not_active Ceased
- 2018-09-28 MX MX2020004084A patent/MX2020004084A/es unknown
- 2018-09-28 US US16/145,768 patent/US10881666B2/en active Active
- 2018-09-28 WO PCT/US2018/053361 patent/WO2019067864A1/en not_active Ceased
- 2018-10-01 TW TW107134652A patent/TWI794297B/zh not_active IP Right Cessation
-
2020
- 2020-05-04 ZA ZA2020/02139A patent/ZA202002139B/en unknown
- 2020-11-10 US US17/094,029 patent/US12268694B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536069A5 (https=) | ||
| JP2018507861A5 (https=) | ||
| US8362018B2 (en) | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | |
| US8436004B2 (en) | Bicycloaniline derivative | |
| TWI409262B (zh) | 二氫吡唑并嘧啶酮衍生物 | |
| US8329711B2 (en) | Pyridone-substituted-dihydropyrazolopyrimidinone derivative | |
| CA2552107A1 (en) | Pyrrolotriazine compounds as kinase inhibitors | |
| US8586584B2 (en) | Compounds for the treatment of hepatitis C | |
| CN114174303B (zh) | 作为sting激动剂的大环化合物及其方法和用途 | |
| US20200115389A1 (en) | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors | |
| ES2271221T3 (es) | Derivados imidazo-pirimidina como ligandos para receptores gaba. | |
| JP2011508782A5 (https=) | ||
| JP2015511245A5 (https=) | ||
| JP2016538316A (ja) | 抗ウイルス化合物 | |
| TW201842919A (zh) | 經修飾環二核苷酸化合物 | |
| WO2004096128A2 (en) | Hiv integrase inhibitors | |
| ES2753777T3 (es) | Compuestos novedosos de sulfonimidoilpurinona y derivados para el tratamiento y la profilaxis de infecciones víricas | |
| CA2351709A1 (en) | Novel triazolo(4,5-d)pyrimidine compounds | |
| JP2013510904A5 (https=) | ||
| US20160115149A1 (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| RU2014126750A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2005524609A5 (https=) | ||
| AU2016335086B2 (en) | Quinoxaline and pyridopyrazine derivatives as pI3Kbeta inhibitors | |
| JP2021523177A5 (https=) | ||
| JP2006512366A5 (https=) |